Adaptin Bio (APTN) Accumulated Expenses (2024 - 2026)

Adaptin Bio has disclosed Accumulated Expenses across 3 years of filings, most recently posting $272381.0 for Q1 2026.

• Quarterly Accumulated Expenses fell 59.84% year-over-year to $272381.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $272381.0 (down 59.84% YoY) and the FY2025 annual result came in at $424595.0, up 214.81% from the prior year.
• Accumulated Expenses slipped to $272381.0 in Q1 2026, from $424595.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $678278.0 in Q1 2025 and bottomed at $134875.0 in Q4 2024.
• The 3-year median for Accumulated Expenses is $427550.5 (2025), against an average of $410381.8.
• Year-over-year, Accumulated Expenses jumped 214.81% in 2025 and plunged 59.84% in 2026.
• Adaptin Bio's Accumulated Expenses stood at $134875.0 in 2024, then jumped by 214.81% to $424595.0 in 2025, then plunged by 35.85% to $272381.0 in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $272381.0, $424595.0, and $430506.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.